Prime Medicine (PRME) Common Equity (2021 - 2025)
Prime Medicine (PRME) has disclosed Common Equity for 5 consecutive years, with $120.9 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Common Equity fell 21.08% year-over-year to $120.9 million, compared with a TTM value of $120.9 million through Dec 2025, down 21.08%, and an annual FY2025 reading of $120.9 million, down 21.08% over the prior year.
- Common Equity was $120.9 million for Q4 2025 at Prime Medicine, down from $161.8 million in the prior quarter.
- Across five years, Common Equity topped out at $316.3 million in Q4 2022 and bottomed at -$223.1 million in Q3 2022.
- Average Common Equity over 5 years is $86.7 million, with a median of $143.1 million recorded in 2023.
- Peak annual rise in Common Equity hit 302.43% in 2022, while the deepest fall reached 136.29% in 2022.
- Year by year, Common Equity stood at -$156.2 million in 2021, then soared by 302.43% to $316.3 million in 2022, then plummeted by 57.92% to $133.1 million in 2023, then grew by 15.09% to $153.1 million in 2024, then dropped by 21.08% to $120.9 million in 2025.
- Business Quant data shows Common Equity for PRME at $120.9 million in Q4 2025, $161.8 million in Q3 2025, and $60.9 million in Q2 2025.